Pharmedic Pharmaceutical Medicinal JSC (HNX:PMC)
Vietnam
· Delayed Price · Currency is VND 117,500
0.00 (0.00%)
At close: Apr 11, 2025
HNX:PMC Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 | 2016 - 2020 |
| Net Income | 80,133 | 83,564 | 83,416 | 64,760 | 74,618 | Upgrade
|
| Depreciation & Amortization | 11,271 | 11,938 | 12,543 | 13,968 | 14,353 | Upgrade
|
| Other Amortization | 161.53 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | -9,496 | -19,973 | -14,121 | -8,762 | -8,062 | Upgrade
|
| Provision & Write-off of Bad Debts | 31.82 | -452.19 | -407.62 | 250.65 | 824.01 | Upgrade
|
| Other Operating Activities | -25,378 | -17,783 | -24,712 | -12,664 | -18,492 | Upgrade
|
| Change in Accounts Receivable | -14,356 | -5,505 | 3,870 | -4,925 | 23,945 | Upgrade
|
| Change in Inventory | -3,875 | 37,302 | -33,167 | 18,035 | 3,868 | Upgrade
|
| Change in Accounts Payable | 16,445 | 6,564 | 7,741 | -6,550 | -8,460 | Upgrade
|
| Change in Other Net Operating Assets | -955.6 | -965.78 | 1,831 | -1,266 | -1,904 | Upgrade
|
| Operating Cash Flow | 53,981 | 94,690 | 36,993 | 62,847 | 80,690 | Upgrade
|
| Operating Cash Flow Growth | -42.99% | 155.97% | -41.14% | -22.11% | 239.35% | Upgrade
|
| Capital Expenditures | -14,754 | -8,012 | -5,318 | -3,962 | -9,687 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 175.45 | 1,253 | 334.97 | 259.09 | Upgrade
|
| Investment in Securities | 108,000 | 7,100 | -13,969 | -130,631 | -111,500 | Upgrade
|
| Other Investing Activities | 10,144 | 19,392 | 11,834 | 7,473 | 7,633 | Upgrade
|
| Investing Cash Flow | 103,390 | 18,656 | -6,200 | -126,785 | -113,294 | Upgrade
|
| Common Dividends Paid | -110,542 | -137,548 | -22,770 | -21,655 | -22,096 | Upgrade
|
| Dividends Paid | -110,542 | -137,548 | -22,770 | -21,655 | -22,096 | Upgrade
|
| Financing Cash Flow | -110,542 | -137,548 | -22,770 | -21,655 | -22,096 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.37 | 1.08 | 0.99 | -3.61 | 1.6 | Upgrade
|
| Net Cash Flow | 46,832 | -24,201 | 8,024 | -85,596 | -54,699 | Upgrade
|
| Free Cash Flow | 39,227 | 86,678 | 31,675 | 58,885 | 71,003 | Upgrade
|
| Free Cash Flow Growth | -54.74% | 173.65% | -46.21% | -17.07% | 392.46% | Upgrade
|
| Free Cash Flow Margin | 7.87% | 17.87% | 6.71% | 14.21% | 15.41% | Upgrade
|
| Free Cash Flow Per Share | 4203.23 | 9287.65 | 3394.02 | 6309.63 | 7608.06 | Upgrade
|
| Cash Income Tax Paid | 21,421 | 20,581 | 20,903 | 13,523 | 21,617 | Upgrade
|
| Levered Free Cash Flow | 38,747 | 104,285 | 37,573 | 65,033 | 100,345 | Upgrade
|
| Unlevered Free Cash Flow | 38,747 | 104,285 | 37,573 | 65,033 | 100,345 | Upgrade
|
| Change in Net Working Capital | 14,483 | -47,605 | 26,381 | -9,664 | -42,124 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.